Osteoarthritis Patient-Focused Drug Development
The OA Voice of the Patient Report is the culmination of the Arthritis Foundation’s efforts to engage patients in all aspects of treatment development for arthritis patients. To accomplish this end for patients with Osteoarthritis (OA), the Arthritis Foundation hosted an OA Patient-Focused Drug Development (PFDD) meeting in the Washington, D.C. area on March 8, 2017. This meeting provided the U.S. Food and Drug Administration (FDA), drug developers, health care providers, academic researchers, and other stakeholders an opportunity to hear directly from patients, patient advocates and caretakers about the signs and symptoms that matter most to them. OA patients shared just how much this disease impacts their lives, as well as the gaps in treatment and what they are looking for in ideal, new treatment options.
The OA Voice of the Patient Report reflects these patients’ lived experiences and what they feel is important about their disease and treatments, from a patient-perspective. The Arthritis Foundation recommends that these findings be strongly considered when developing regulatory guidance for new treatments.
The meeting was a tremendous step in the right direction in bringing patients new treatments to market.
Osteoarthritis Patient-Focused Drug Development Meeting
FDA Discusses the Importance of PFDD Meetings
Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research at the FDA, talk about the importance of PFDD meetings and how they are impactful for both participants and the FDA. Watch the video here.
Advancing Osteoarthritis Treatment Webinar
In an effort to collect information from Osteoarthritis (OA) patients about their experiences with OA, we hosted a webinar for OA patients on January 31, 2017. Patients responded to questions about their experiences with OA including treatments and asked a rheumatologist and orthopedic surgeon questions about their disease and the future of treatments. Watch the webinar here.
In addition to the webinar, we hosted five focus groups around the country to collect critical information about the impact of OA. They were held in Indianapolis, Indiana; West Palm Beach, Florida; New York City, New York; Phoenix, Arizona; and San Leandro, California. In each of these conversations we collected insights about the true impact of this debilitating disease, what patients’ experiences have been with the treatments currently available, and what the OA community hopes for in treatments of the future.